Cargando…
BU-32: a novel proteasome inhibitor for breast cancer
INTRODUCTION: Proteasome inhibition provides an attractive approach to cancer therapy and may have application in the treatment of breast cancer. However, results of recent clinical trials to evaluate the effect of the proteasome inhibitor Bortezomib (Velcade(®), also called PS-341) in metastatic br...
| Autores principales: | , , , , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2009
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2790855/ https://www.ncbi.nlm.nih.gov/pubmed/19821999 http://dx.doi.org/10.1186/bcr2411 |